![](https://insights.axtria.com/hubfs/Everest%20Group%20Life%20Sciences%20Digital%20Services%20Specialists.png)
Trending
Everest Group Life Sciences Digital Services Specialists PEAK Matrix® Assessment 2024
We’re proud to have been named a Leader in the Everest Group Life Sciences Digital Services Specialists PEAK Matrix® Report. Everest Group classified ...
![From Chaos to Cohesion](https://insights.axtria.com/hs-fs/hubfs/From%20Chaos%20to%20Cohesion-1.jpg?width=234&height=327&name=From%20Chaos%20to%20Cohesion-1.jpg)
R&D
![Importation Of Drugs Is Back Again On The Pharma Public Policy Table – A Short Commentary](https://insights.axtria.com/hubfs/Rare%20Diseases%20-%20Challenges%20Associated%20With%20Orphan%20Drug%20Commercialization.png)
Importation Of Drugs Is Back Again On The Pharma Public Policy Table – A Short Commentary
The importation of drugs from lower-priced countries, like Canada, was an idea brought up during the Clinton Administration as a way for consumers to bypass the high cost of prescription drugs in the US. The effect of allowing importation is essentially about the imposition of a foreign drug price control on the US market. The economic analysis of the adverse effects of price controls on R&D ...
![Latest Pharma R&D Cost Estimates – Implications For The Expanded Use Of Commercial Analytics](https://insights.axtria.com/hubfs/A%20Custom-Built%20Hierarchy%20Management%20System%20To%20Facilitate%20On-Demand%20Commercial%20Analytics%20And%20AI_ML%20Models.jpg)
Latest Pharma R&D Cost Estimates – Implications For The Expanded Use Of Commercial Analytics
The latest pharma R&D cost estimates illustrate that greater pressures will increasingly be placed on companies to find greater cost efficiencies, reduce risks, improve pipeline productivity, and sustain a ROI on R&D spending needed for long-term drug development and commercial success. This means companies must look beyond current applications of commercial analytics focused mainly on ...